Disruptive diagnostic for bacterial infection directly from whole blood in patients with SEPSIS

败血症是医院死亡的主要原因，每年约有70万人死于欧盟。要治疗败血症感染，我们必须确定引起感染的病原体，并确定它们的抗生素敏感性。然而，现有的血培养检测速度很慢(几天)，而败血症死亡很快(几个小时)。因此，临床医生开始使用广谱抗生素进行治疗。这些都是次优的，可能会对一些患者有害。在没有诊断结果的情况下开始治疗也会导致过度使用抗生素，影响抗菌素耐药性。许多人试图使用直接从血液中提取的(DFB)检测方法来应对这一挑战，但未能满足真正的市场需求。SepsiSTAT是世界上第一个DFB诊断平台，能够提供血培养检测的可信替代方案，但结果只需几小时而不是几天。这使得能够快速瞄准抗生素治疗，改善患者结果，提高医疗效率，并减少抗生素的使用。

Sepsis is the leading cause of hospital death with ~700K EU deaths annually. To treat a sepsis infection, we must identify the causative pathogens and determine their antibiotic susceptibility. However, existing blood culture testing is slow (days) and sepsis kills quickly (hours). Clinicians therefore initiate treatment with broad-spectrum antibiotics. These are sub-optimal and can be harmful to some patients. Initiation of treatment without diagnostic results also leads to overuse of antibiotics, impacting antimicrobial resistance. Many have sought to address this challenge using direct from-blood (DfB) test methods, but have failed to address the real market need. SepsiSTAT is the world’s first DfB diagnostic platform able to deliver a credible alternative to blood culture testing, but with results in hours and not days. This enables a rapid targeting of antibiotic treatments with improved patient outcomes, greater healthcare efficiencies and reduced antibiotic use.